SUPN
Supernus Pharmaceuticals, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
45.85
▼ 1.60 (3.37%)
MARKET · —
Price
Open
47.13
Prev close
47.45
Day high
47.82
Day low
45.79
Volume
724.76K
Market cap
$2.67B
P/E (TTM)
—
52W range
42.45 – 59.68
Trailing performance
Returnvs SPY
1W
-5.01%
-3.6%
1M
-2.84%
-6.6%
3M
-7.15%
-10.2%
6M
-9.85%
-20.9%
YTD
-7.75%
-20.0%
1Y
+7.43%
-12.6%
3Y
+48.14%
-26.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$2.67B
Enterprise value$2.33B
Revenue (TTM)$830.44M
Gross profit$605.31M
EBITDA$110.43M
Net income$-109.89M
EPS (TTM)$-1.92
Free cash flow$84.61M
Total cash$372.07M
Total debt$40.17M
Book value / share$17.73
Shares outstanding58.13M
Float51.65M
Short % of float10.18%
Dividend yield—
Beta (5Y)0.56
Valuation & profitability ratios
Trailing P/E—
Forward P/E10.28
PEG ratio—
Price / sales—
Price / book2.59
EV / revenue2.81
EV / EBITDA21.13
Gross margin72.89%
Operating margin-2.48%
Profit margin-13.23%
Return on equity-10.49%
Return on assets0.39%
Debt / equity3.90
Current ratio2.08
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $718.95M | $661.82M | $607.52M | $667.24M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$38.55M | $73.86M | $1.32M | $60.71M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$38.55M | $73.86M | $1.32M | $60.71M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.51 | 0.53 | +4.1% |
| Mar 2026 | 0.28 | 0.21 | -24.5% |
| Dec 2025 | 0.28 | 0.88 | +215.0% |
| Sep 2025 | 0.82 | 0.61 | -25.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.62 | 2 | $220.72M | +14.9% |
| Next quarter | 1.09 | 2 | $238.30M | +12.6% |
| Current year | 2.57 | 2 | $885.80M | +23.2% |
| Next year | 4.46 | 2 | $1.37B | +54.9% |
Analyst targets & ownership
Mean target$61.75
High target$67.00
Low target$55.00
Implied upside34.68%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy0 / 3
Hold1
Sell / Strong sell0 / 0
Held by insiders4.49%
Held by institutions106.69%
Institutions holding460
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+83.91K
Net buying
Buy transactions
25
265.29K shares
Sell transactions
7
181.38K shares
Net transactions
+32
Buys less sells
Sell : buy shares
0.7 : 1
Mixed
Insider-held shares
2.61M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 12, 26 | KHATTAR JACK A Chief Executive Officer |
— | 29.85K | — | Direct |
| Aug 12, 26 | DEC TIMOTHY C Chief Financial Officer |
— | 1.25K | — | Direct |
| Aug 12, 26 | BHATT PADMANABH P Officer |
— | 2.50K | — | Direct |
| Aug 12, 26 | MOTTOLA FRANK Chief Technology Officer |
— | 1.65K | — | Direct |
| Aug 12, 26 | RUBIN JONATHAN Officer |
— | 750 | — | Direct |
| Mar 18, 26 | BHATT PADMANABH P Officer |
SELL | 107.25K | $5.39M | Direct |
| Mar 18, 26 | BHATT PADMANABH P Officer |
CONVERSION | 107.25K | $3.89M | Direct |
| Mar 13, 26 | KHATTAR JACK A Chief Executive Officer |
SELL | 35.00K | $1.76M | Indirect |
| Mar 12, 26 | HUDSON FREDERICK M Director |
SELL | 5.37K | $271.73K | Direct |
| Mar 10, 26 | HORICH WILLIAM TODD Officer |
SELL | 8.88K | $483.80K | Direct |
| Mar 9, 26 | MOTTOLA FRANK Chief Operating Officer |
SELL | 1.62K | $87.07K | Direct |
| Mar 6, 26 | GEMAYEL GEORGES PH.D. Director |
SELL | 18.79K | $1.00M | Direct |
| Mar 6, 26 | KHATTAR JACK A Chief Executive Officer |
— | 38.64K | — | Direct |
| Mar 6, 26 | DEC TIMOTHY C Chief Financial Officer |
— | 6.00K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARLOW CARROLEE |
Director | 27.05K | Stock Award(Grant) |
BHATT PADMANABH P |
Officer | 18.64K | Conversion of Exercise of derivative security |
DEC TIMOTHY C |
Chief Financial Officer | 9.13K | Conversion of Exercise of derivative security |
GEMAYEL GEORGES PH.D. |
Director | 27.28K | Sale |
HUDSON FREDERICK M |
Director | 60.41K | Sale |
KHATTAR JACK A |
Chief Executive Officer | 2.22M | Conversion of Exercise of derivative security |
MOTTOLA FRANK |
Chief Technology Officer | 19.54K | Conversion of Exercise of derivative security |
NEWHALL CHARLES W III |
Director | 124.12K | Stock Award(Grant) |
RUBIN JONATHAN |
Officer | 13.98K | Conversion of Exercise of derivative security |
SENSENIG BETHANY |
Director | 0 | Sale |
Moving averages & technicals
SMA 10
47.64
-3.75% from price
SMA 20
46.92
-2.29% from price
SMA 50
46.69
-1.81% from price
SMA 100
47.80
-4.08% from price
SMA 200
48.63
-5.71% from price
EMA 12
47.37
-3.21% from price
EMA 26
47.17
-2.80% from price
EMA 50
47.17
-2.80% from price
RSI (14)
44.6
Neutral
MACD (12,26,9)
0.20
Hist 0.00
ATR (14)
1.95
4.26% of price
Realised vol 30D
40.5%
Annualised
Bollinger upper
49.60
20, 2σ
Bollinger lower
44.25
20, 2σ
50 / 200 cross
Death
46.69 vs 48.63
Trend bias
Below 200
-5.71%
Risk profile
Beta vs SPY
0.46
Less volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
40.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-24.1%
Peak to trough
Max drawdown 5Y
-45.9%
Peak to trough
ATR 14
1.95
4.26% of price
Beta (reported)
0.56
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
1.68
Put-heavy session
Put / call open interest
0.91
Positioning, not flow
Max pain
45.00
-1.9% from spot
ATM implied vol
58.9%
Nearest strike to spot
Skew (10% OTM)
+16.0%
Puts bid over calls
Call volume
22
Contracts, this expiry
Put volume
37
Contracts, this expiry
Heaviest call OI
55.00
22 contracts
Heaviest put OI
49.00
20 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Zacks · 24h ago
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
Zacks · 1d ago
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
Zacks · 2d ago
1 Healthcare Stock with Exciting Potential and 2 We Ignore
StockStory · 4d ago
3 Russell 2000 Stocks We Approach with Caution
StockStory · 6d ago
Supernus Pharmaceuticals (SUPN) Stock May Be A Bargain After Merger News
Simply Wall St. · 11d ago
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
Zacks · 15d ago
New Strong Buy Stocks for August 7th
Zacks · 15d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.